Evolocumab shows clear benefit in preventing first-time heart attacks and strokes Adding the PCSK9 inhibitor evolocumab to standard lipid-lowering therapy significantly reduced first major cardiovascular events in adults with atherosclerosis or high-risk diabetes who had never had a heart attack or stroke. The 4.6-year study confirmed durable safety and benefit, supporting earlier, more intensive LDL cholesterol control.
https://www.news-medical.net/n....ews/20251111/Evolocu